Fig. 8.

Combined results of 3 whole brain analyses during decision phase where activation in non-users was greater that in casual meth-users, from Fig. 2, Fig. 5, Fig. 6) identifying the overlapping areas: (1) - All trials contrasted with baseline, (2) – risk-modulated activation in safe trials contrasted with risky trials, (3) – reward-modulated activation in safe trials contrasted with risky trials.